A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
2012 · Breast Cancer Research and Treatment · 85 citations
https://doi.org/10.1007/s10549-012-2126-1
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
25
Papers
3.1K
Citations
12
h-index
14
i10-index
Jean Luc Canon is an academic researcher from Grand Charleroi Hospital. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies. The author has an h-index of 12, co-authored 22 publications.
https://doi.org/10.1007/s10549-012-2126-1
https://doi.org/10.1016/j.esmoop.2023.102041
Click to start Chat